SciSparc Ltd. Closes Previously Announced $8.15 Million Private Placement

SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that it has closed its previously announced private placement. In this placement, SciSparc raised aggregate gross proceeds of approximately $8.15 million.

Aegis Capital Corp. acted as Exclusive Placement Agent in the United States in connection with the offering. The securities were sold in a private placement, have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from . . .